Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1428
{ "count": 24555, "next": "http://api.gregory-ms.com/articles/?format=api&page=1429", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1427", "results": [ { "article_id": 381419, "title": "The occurrence of dystonia in upper-limb multiple sclerosis tremor", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> The pathophysiology of multiple sclerosis (MS) tremor is uncertain with limited phenotypical studies available. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate whether dystonia contributes to MS tremor and its severity. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> MS patients ( n = 54) with and without disabling uni- or bilateral upper limb tremor were recruited (39 limbs per group). We rated tremor severity, writing and Archimedes spiral drawing; cerebellar dysfunction (SARA score); the Global Dystonia Scale (GDS) for proximal and distal upper limbs, dystonic posturing, mirror movements, geste antagoniste, and writer’s cramp. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Geste antagoniste, mirror dystonia, and dystonic posturing were more frequent and severe ( p < 0.001) and dystonia scores were correlated with tremor severity in tremor compared to non-tremor patients. A 1-unit increase in distal dystonia predicted a 0.52-Bain unit (95% confidence interval (CI) 0.08–0.97), p = 0.022) increase in tremor severity and a 1-unit (95% CI 0.48–1.6, p = 0.001) increase in drawing scores. A 1-unit increase in proximal dystonia predicted 0.93-Bain unit increase (95% CI 0.45–1.41, p < 0.001) in tremor severity and 1.5-units (95% CI 0.62–2.41, p = 0.002) increase in the drawing score. Cerebellar function in the tremor limb and tremor severity was correlated ( p < 0.001). </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Upper limb dystonia is common in MS tremor suggesting that MS tremor pathophysiology involves cerebello-pallido-thalamo-cortical network dysfunction. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458515577690", "published_date": "2015-05-26T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 290141, "given_name": "A", "family_name": "Van der Walt", "ORCID": null, "country": null }, { "author_id": 290142, "given_name": "K", "family_name": "Buzzard", "ORCID": null, "country": null }, { "author_id": 290143, "given_name": "S", "family_name": "Sung", "ORCID": null, "country": null }, { "author_id": 282589, "given_name": "T", "family_name": "Spelman", "ORCID": null, "country": null }, { "author_id": 290145, "given_name": "SC", "family_name": "Kolbe", "ORCID": null, "country": null }, { "author_id": 290146, "given_name": "M", "family_name": "Marriott", "ORCID": null, "country": null }, { "author_id": 281525, "given_name": "H", "family_name": "Butzkueven", "ORCID": null, "country": null }, { "author_id": 290147, "given_name": "A", "family_name": "Evans", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "The occurrence", "dystonia", "upper-limb multiple sclerosis tremor" ], "doi": "10.1177/1352458515577690", "access": "restricted", "takeaways": " The pathophysiology of MS tremor is uncertain with limited phenotypical studies available . We rated tremor severity, writing and Archimedes spiral drawing; cerebellar dysfunction (SARA score) for proximal and distal upper limbs, dystonic posturing, mirror movements, geste antagoniste, and writer’s cramp . Results: Geste antagoniste and mirror dystonia were more frequent and severe ( p < 0.001) and dy", "categories": [] }, { "article_id": 381559, "title": "The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Multiple sclerosis (MS) relapses contribute to disability and influence treatment decisions. Many centres now provide open access to specialist services for patients with new symptoms. However, there is scarce literature on the spectrum of presentations encountered in this setting. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> The objective of this paper is to characterise presentations to an open, rapid-access MS relapse clinic and the impact on disease management. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> A retrospective review of outpatient episodes over a three-year period was conducted. Demographic and service data, symptoms, disability, diagnosis and management were recorded according to a standardised proforma. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 371 attendances were analysed. A new MS relapse was diagnosed in 216 (58%) episodes, of which 56 (26%) patients had an additional diagnosis which had also contributed to their presentation. Of 266 reports of non-relapse-related symptoms, 73 were unrelated to MS. Treatment interventions were made in almost all relapsing patients and in 70% of patients presenting with acute, non-relapse-related symptoms of MS. Changes to disease-modifying therapies were considered in 28% of consultations. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Diagnosing MS relapses is crucial for disease management and yet remains challenging. Clinicians should be aware of differential diagnoses and confounding factors. The high incidence of therapeutic interventions observed suggests that rapid-access clinics represent an effective platform for responsive disease management. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458514549402", "published_date": "2014-06-18T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 253931, "given_name": "Emma C", "family_name": "Tallantyre", "ORCID": null, "country": null }, { "author_id": 332676, "given_name": "Emmie G", "family_name": "Causon", "ORCID": null, "country": null }, { "author_id": 273777, "given_name": "Katharine E", "family_name": "Harding", "ORCID": null, "country": null }, { "author_id": 256906, "given_name": "Trevor P", "family_name": "Pickersgill", "ORCID": null, "country": null }, { "author_id": 230375, "given_name": "Neil P", "family_name": "Robertson", "ORCID": "http://orcid.org/0000-0002-5409-4909", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "The aetiology", "acute neurological decline", "multiple sclerosis", "Experience", "an open-access clinic" ], "doi": "10.1177/1352458514538333", "access": "restricted", "takeaways": " Multiple sclerosis relapses contribute to disability and influence treatment decisions . Many centres now provide open access to specialist services for patients with new symptoms . There is scarce literature on the spectrum of presentations encountered in this setting .", "categories": [] }, { "article_id": 381807, "title": "The economic impact of multiple sclerosis in Australia in 2010", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Multiple sclerosis (MS) has a major impact on health and is a substantial burden on patients and society. We estimated the annual costs of MS in Australia from individual and societal perspectives using data from the Australian MS Longitudinal Study (AMSLS) and prevalence figures from 2010. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Direct and indirect costs were estimated from a subsample of 712 AMSLS subjects who completed baseline and follow-up economic impact surveys. All costs are in 2010 Australian dollars (AUD). </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Annual costs per person with MS were AUD48,945 (95% CI: 45,138 to 52,752). Total costs were AUD1.042 (0.9707 to 1.1227) billion based on a prevalence of 21,283. The largest component was indirect costs due to loss of productivity (48%). Costs increased with increasing disability: AUD36,369, AUD58,890 and AUD65,305 per patient per year for mild, moderate and severe disability, respectively. Total costs of MS to Australian society have increased 58% between 2005 and 2010. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> This study confirms that MS imposes a substantial burden on Australian society, particularly impacting on productivity. The burden increases with worsening disability associated with the disease. Investment in interventions that slow progression, as well as resources, services and environments that assist people with MS to retain employment, is supported. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513494959", "published_date": "2013-05-07T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 246576, "given_name": "Andrew J", "family_name": "Palmer", "ORCID": null, "country": null }, { "author_id": 246583, "given_name": "Sam", "family_name": "Colman", "ORCID": null, "country": null }, { "author_id": 246581, "given_name": "Beth", "family_name": "O’Leary", "ORCID": null, "country": null }, { "author_id": 177179, "given_name": "Bruce V.", "family_name": "Taylor", "ORCID": "http://orcid.org/0000-0003-2807-0070", "country": "AU" }, { "author_id": 254081, "given_name": "Rex D", "family_name": "Simmons", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "The economic impact", "multiple sclerosis", "Australia" ], "doi": "10.1177/1352458513488230", "access": "restricted", "takeaways": " Multiple sclerosis (MS) has a major impact on health and is a substantial burden on patients and society . Annual costs per person with MS were AUD48,945 (95% CI: 45,138 to 52,752) Total costs of MS to Australian society have increased 58% between 2005 and 2010 .", "categories": [] }, { "article_id": 381821, "title": "Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To evaluate the treatment effect of alemtuzumab on low-contrast vision in relapsing–remitting multiple sclerosis (RRMS) patients. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> This was a pre-defined exploratory analysis within a randomized, rater-blinded trial (CAMMS223) that was run at 49 academic medical centers in the US and in Europe. Patients with untreated, early, RRMS (McDonald, n = 334) were randomized 1:1:1 to subcutaneous interferon beta-1a (IFNB-1a), or alemtuzumab 12 mg or 24 mg. Visual contrast sensitivity was measured for each eye at baseline and quarterly, with Pelli-Robson charts. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The eyes of patients in the pooled alemtuzumab group (versus IFNB-1a) had a greater than 2-fold higher rate of both 3-month and 6-month sustained visual improvement, of at least 0.3 log units (2 triplets, 6 letters) (At 3 months the hazard ratio (HR) = 2.26; CI = 1.19 to 4.31; P = 0.013; and at 6 months the HR = 2.44; CI =1.16 to 5.15; P = 0.019), and they had a lower risk of 3- and 6-month sustained worsening of at least 0.15 log units (1 triplet, 3 letters) (At 3 months the HR = 0.58; CI = 0.38 to 0.89; P = 0.012; and at 6 months HR = 0.55; CI=0.35 to 0.87; P = 0.010). Over the 36-month study period, the eyes of patients in the pooled alemtuzumab group improved in mean contrast sensitivity to a greater extent than those in the IFNB-1a group (0.080 log units versus 0.038 log units; P = 0.0102). </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Alemtuzumab was associated with a greater chance of improved contrast sensitivity in patients with RRMS and may delay the worsening of visual function. Contrast sensitivity testing was sensitive to treatment effects, even within an active comparator study design. These results support the validity of low-contrast vision testing as a clinical outcome in MS trials. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513494959", "published_date": "2013-03-04T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 159536, "given_name": "Jennifer", "family_name": "Graves", "ORCID": "http://orcid.org/0000-0003-1539-1940", "country": null }, { "author_id": 241913, "given_name": "Steven L", "family_name": "Galetta", "ORCID": null, "country": null }, { "author_id": 292514, "given_name": "Jeffrey", "family_name": "Palmer", "ORCID": null, "country": null }, { "author_id": 267079, "given_name": "David H", "family_name": "Margolin", "ORCID": null, "country": null }, { "author_id": 292516, "given_name": "Marco", "family_name": "Rizzo", "ORCID": null, "country": null }, { "author_id": 292517, "given_name": "John", "family_name": "Bilbruck", "ORCID": null, "country": null }, { "author_id": 266349, "given_name": "Laura J", "family_name": "Balcer", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Alemtuzumab", "contrast sensitivity", "patients", "multiple sclerosis" ], "doi": "10.1177/1352458513475722", "access": "open", "takeaways": " Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes . Patients with untreated, early, early RRMS (McDonald, n = 334) were randomized 1:1:1 to subcutaneous interferon beta-1a (IFNB-1) or alemtuzumac 12 mg or 24 mg . Over the 36-month study period, the eyes of patients in the pooled alem", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 117 } ] }, { "article_id": 380699, "title": "Dalfampridine benefits ambulation but not cognition in multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Impaired cognition and ambulation are common in multiple sclerosis (MS). Dalfampridine is the first Food and Drug Administration (FDA)–approved medication to treat impaired ambulation in MS. Dalfampridine may benefit patients with cognitive impairment, given its effects on saltatory conduction and the association between cognitive and motor function. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To examine the effects of dalfampridine on cognition in MS. To determine if the anticipated improved cognition is grounded in dalfampridine’s effects on ambulation. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Adults with MS were randomized to dalfampridine ( n = 45) or placebo ( n = 16) for 12 weeks. Cognition and motor function were assessed at baseline and end-point. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> T25FW and 6-minute walk (6MW) performance improved at end-point in the treatment group but not in the placebo group ( p < 0.05). Our primary outcome, performance on the Symbol Digit Modalities Test, did not improve. About 30% ( n = 12) of the dalfampridine group demonstrated ⩾20% improved ambulation and were categorized “responders.” Among “responders”, Symbol Digit Modalities test performance did not improve. However, performance on the Paced Auditory Serial Addition Test improved among “responders” ( p < 0.05). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Dalfampridine benefits timed ambulation but not cognition. Some improvement among ambulation “responders” is consistent with prior reports of cognition-motor coupling in MS ( ClinicalTrials.gov #: NCT02006160). </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518815795", "published_date": "2018-12-19T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 268557, "given_name": "Nikhil", "family_name": "Satchidanand", "ORCID": null, "country": null }, { "author_id": 251282, "given_name": "Allison", "family_name": "Drake", "ORCID": null, "country": null }, { "author_id": 268559, "given_name": "A", "family_name": "Smerbeck", "ORCID": null, "country": null }, { "author_id": 249035, "given_name": "David", "family_name": "Hojnacki", "ORCID": null, "country": null }, { "author_id": 249024, "given_name": "Channa", "family_name": "Kolb", "ORCID": null, "country": null }, { "author_id": 268561, "given_name": "Kara", "family_name": "Patrick", "ORCID": null, "country": null }, { "author_id": 152480, "given_name": "Bianca", "family_name": "Weinstock-Guttman", "ORCID": "http://orcid.org/0000-0001-6732-151X", "country": null }, { "author_id": 163418, "given_name": "Robert W", "family_name": "Motl", "ORCID": "http://orcid.org/0000-0002-5894-2290", "country": null }, { "author_id": 237074, "given_name": "Ralph HB", "family_name": "Benedict", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "ambulation", "not cognition", "multiple sclerosis" ], "doi": "10.1177/1352458518815795", "access": "restricted", "takeaways": " Impaired cognition and ambulation are common in multiple sclerosis . Dalfampridine is the first FDA-approved medication to treat impaired ambulation in MS .", "categories": [] }, { "article_id": 381825, "title": "Longitudinal follow-up of vision in a neuromyelitis optica cohort", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Neuromyelitis optica (NMO) is an inflammatory disease associated with optic neuritis and myelitis. Recently, several studies showed that optical coherence tomography (OCT) could be an interesting method for the evaluation of disease severity; however, to date there are no studies with a longitudinal follow-up of visual function in NMO. The aim of this study was to assess the ability of OCT to evaluate the progression of visual dysfunction in NMO. </jats:p></jats:sec><jats:sec><jats:title>Patients and methods:</jats:title><jats:p> A group of 30 NMO patients (thus, 60 eyes), comprised of 20 women and 10 men with a mean age of 43.7 +/− 12.3 years, were prospectively evaluated clinically and by a whole neuro-ophthalmological work-up, including: visual acuity (VA), fundoscopy, visual evoked potential (VEP), visual field (VF) and optical coherence tomography (OCT). All patients were tested at baseline (after a mean disease duration of 6.1 years) and after a mean time of follow-up of 18 months (range: 12–36 months). </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Mean VA was similar at the two evaluation times (0.77 +/− 0.36 versus 0.77 +/− 0.35). The mean VF defect decreased slightly, but the difference was not significant (−5.9 +/− 1.3 dB versus −5.3 +/− 1.3 dB). In contrast, the mean retinal thickness seen on OCT decreased from 87.4 +/− 23.3 µm to 79.7 +/- 22.4 µm ( p = 0.006). These modifications were only observed in eyes with a past or a recent history of optic neuritis (−15.1 µm; p < 0.001) and not in eyes without any history of optic neuritis (−2.4 µm; not significant). Also, they occurred independently of the occurrence of relapses ( n = 13) and especially optic neuritis episodes; however, the number of optic neuritis episodes was low ( n = 5). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> OCT seems to be a more sensitive test than VA or VF for monitoring ophthalmological function in NMO and it seems to be helpful for the detection of infra-clinical episodes in patients with a past history of optic neuritis. Our results suggest that this easily performed technique should be used in the follow-up of NMO, but complementary studies are warranted to confirm its interest at an individual level. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513494959", "published_date": "2013-02-14T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 282357, "given_name": "M", "family_name": "Bouyon", "ORCID": null, "country": null }, { "author_id": 282358, "given_name": "N", "family_name": "Collongues", "ORCID": null, "country": null }, { "author_id": 277748, "given_name": "H", "family_name": "Zéphir", "ORCID": null, "country": null }, { "author_id": 282359, "given_name": "L", "family_name": "Ballonzoli", "ORCID": null, "country": null }, { "author_id": 282360, "given_name": "L", "family_name": "Jeanjean", "ORCID": null, "country": null }, { "author_id": 242045, "given_name": "C", "family_name": "Lebrun", "ORCID": null, "country": null }, { "author_id": 282361, "given_name": "JB", "family_name": "Chanson", "ORCID": null, "country": null }, { "author_id": 277750, "given_name": "F", "family_name": "Blanc", "ORCID": null, "country": null }, { "author_id": 277753, "given_name": "M", "family_name": "Fleury", "ORCID": null, "country": null }, { "author_id": 273467, "given_name": "O", "family_name": "Outteryck", "ORCID": null, "country": null }, { "author_id": 282362, "given_name": "S", "family_name": "Defoort", "ORCID": null, "country": null }, { "author_id": 282363, "given_name": "P", "family_name": "Labauge", "ORCID": null, "country": null }, { "author_id": 250464, "given_name": "P", "family_name": "Vermersch", "ORCID": null, "country": null }, { "author_id": 282364, "given_name": "C", "family_name": "Speeg", "ORCID": null, "country": null }, { "author_id": 282365, "given_name": "J", "family_name": "De Seze", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Longitudinal follow-up", "vision", "a neuromyelitis optica cohort" ], "doi": "10.1177/1352458513476562", "access": "restricted", "takeaways": " Neuromyelitis optica (NMO) is an inflammatory disease associated with optic neuritis and myelitis . The aim of this study was to assess the ability of optical coherence tomography to evaluate the progression of visual dysfunction in NMO .", "categories": [] }, { "article_id": 381865, "title": "Molecular network of chromatin immunoprecipitation followed by deep sequencing-based vitamin D receptor target genes", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Vitamin D is a liposoluble vitamin essential for calcium metabolism. The ligand-bound vitamin D receptor (VDR), heterodimerized with retinoid X receptor, interacts with vitamin D response elements (VDREs) to regulate gene expression. Vitamin D deficiency due to insufficient sunlight exposure confers an increased risk for multiple sclerosis (MS). </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To study a protective role of vitamin D in multiple sclerosis (MS), it is important to characterize the global molecular network of VDR target genes (VDRTGs) in immune cells. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We identified genome-wide VDRTGs collectively from two distinct chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq) datasets of VDR-binding sites derived from calcitriol-treated human cells of B cell and monocyte origins. We mapped short reads of next generation sequencing (NGS) data on hg19 with Bowtie, detected the peaks with Model-based Analysis of ChIP-Seq (MACS), and identified genomic locations by GenomeJack, a novel genome viewer for NGS platforms. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We found 2997 stringent peaks distributed on protein-coding genes, chiefly located in the promoter and the intron on VDRE DR3 sequences. However, the corresponding transcriptome data verified calcitriol-induced upregulation of only a small set of VDRTGs. The molecular network of 1541 calcitriol-responsive VDRTGs showed a significant relationship with leukocyte transendothelial migration, Fcγ receptor-mediated phagocytosis, and transcriptional regulation by VDR, suggesting a pivotal role of genome-wide VDRTGs in immune regulation. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> These results suggest the working hypothesis that persistent deficiency of vitamin D might perturb the complex network of VDRTGs in immune cells, being responsible for induction of an autoimmune response causative for MS. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513489759", "published_date": "2013-02-11T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 294109, "given_name": "Jun-ichi", "family_name": "Satoh", "ORCID": null, "country": null }, { "author_id": 294110, "given_name": "Hiroko", "family_name": "Tabunoki", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Molecular network", "chromatin immunoprecipitation", "deep sequencing-based vitamin D receptor target genes" ], "doi": "10.1177/1352458512471873", "access": "restricted", "takeaways": " Vitamin D is a liposoluble vitamin essential for calcium metabolism . Vitamin D deficiency due to insufficient sunlight exposure confers an increased risk for multiple sclerosis . The ligand-bound vitamin D receptor (VDR) interacts with vitamin D response elements (VDREs) to regulate gene expression .", "categories": [] }, { "article_id": 381098, "title": "CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Imbalance leading to falls is common in people with multiple sclerosis (PwMS). </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To evaluate the effects of a balance group exercise programme (CoDuSe) on balance and walking in PwMS (Expanded Disability Status Scale, 4.0–7.5). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> A multi-centre, randomized, controlled single-blinded pilot study with random allocation to early or late start of exercise, with the latter group serving as control group for the physical function measures. In total, 14 supervised 60-minute exercise sessions were delivered over 7 weeks. Pretest–posttest analyses were conducted for self-reported near falls and falls in the group starting late. Primary outcome was Berg Balance Scale (BBS). A total of 51 participants were initially enrolled; three were lost to follow-up. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Post-intervention, the exercise group showed statistically significant improvement ( p = 0.015) in BBS and borderline significant improvement in MS Walking Scale ( p = 0.051), both with large effect sizes (3.66; −2.89). No other significant differences were found between groups. In the group starting late, numbers of falls and near falls were statistically significantly reduced after exercise compared to before ( p < 0.001; p < 0.004). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> This pilot study suggests that the CoDuSe exercise improved balance and reduced perceived walking limitations, compared to no exercise. The intervention reduced falls and near falls frequency. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458516677591", "published_date": "2016-11-12T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 268688, "given_name": "Anna", "family_name": "Carling", "ORCID": null, "country": null }, { "author_id": 268689, "given_name": "Anette", "family_name": "Forsberg", "ORCID": null, "country": null }, { "author_id": 246280, "given_name": "Martin", "family_name": "Gunnarsson", "ORCID": null, "country": null }, { "author_id": 166024, "given_name": "Ylva", "family_name": "Nilsagård", "ORCID": "http://orcid.org/0000-0002-9760-3785", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "CoDuSe group exercise programme", "balance", "people", "multiple sclerosis", "A multi-centre, randomized, controlled pilot study" ], "doi": "10.1177/1352458516677591", "access": "open", "takeaways": " Imbalance leading to falls is common in people with multiple sclerosis (PwMS) The CoDuSe exercise programme (CoDuSe) reduced falls and near falls frequency .", "categories": [] }, { "article_id": 382113, "title": "Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach", "summary": "<jats:p> Background: Several authors have used advanced magnetic resonance imaging (MRI) techniques to investigate whether patients with neuromyelitis optica (NMO) have occult damage in normal-appearing brain tissue, similarly to multiple sclerosis (MS). To date, the literature contains no data derived from the combined use of several advanced MRI techniques in the same NMO subjects. </jats:p><jats:p> Objective: We set out to determine whether occult damage could be detected in the normal-appearing brain tissue of a small group of patients with NMO using a multiparametric MRI approach. </jats:p><jats:p> Methods: Eight female patients affected by NMO (age range 44–58 years) and seven sex- and age-matched healthy controls were included. The techniques used on a 1.5 T MRI imaging scanner were magnetization transfer imaging, diffusion tensor imaging, tract-based spatial statistics, spectroscopy and voxel-based morphometry in order to analyse normal-appearing white matter and normal-appearing grey matter. </jats:p><jats:p> Results: Structural and metabolic parameters showed no abnormalities in normal-appearing white matter of patients with NMO. Conversely, tract-based spatial statistics demonstrated a selective alteration of the optic pathways and the lateral geniculate nuclei. Diffusion tensor imaging values in the normal-appearing grey matter were found to be significantly different in the patients with NMO versus the healthy controls. Moreover, voxel-based morphometry analysis demonstrated a significant density and volume reduction of the sensorimotor cortex and the visual cortex. </jats:p><jats:p> Conclusions: Our data disclosed occult structural damage in the brain of patients with NMO, predominantly involving regions connected with motor and visual systems. This damage seems to be the direct consequence of transsynaptic degeneration triggered by lesions of the optic nerve and spine. </jats:p>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458512440349", "published_date": "2011-12-19T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 266831, "given_name": "A", "family_name": "Pichiecchio", "ORCID": null, "country": null }, { "author_id": 266832, "given_name": "E", "family_name": "Tavazzi", "ORCID": null, "country": null }, { "author_id": 266833, "given_name": "G", "family_name": "Poloni", "ORCID": null, "country": null }, { "author_id": 266834, "given_name": "M", "family_name": "Ponzio", "ORCID": null, "country": null }, { "author_id": 266835, "given_name": "F", "family_name": "Palesi", "ORCID": null, "country": null }, { "author_id": 266836, "given_name": "M", "family_name": "Pasin", "ORCID": null, "country": null }, { "author_id": 266837, "given_name": "L", "family_name": "Piccolo", "ORCID": null, "country": null }, { "author_id": 266838, "given_name": "D", "family_name": "Tosello", "ORCID": null, "country": null }, { "author_id": 266839, "given_name": "A", "family_name": "Romani", "ORCID": null, "country": null }, { "author_id": 266840, "given_name": "R", "family_name": "Bergamaschi", "ORCID": null, "country": null }, { "author_id": 266841, "given_name": "G", "family_name": "Piccolo", "ORCID": null, "country": null }, { "author_id": 266842, "given_name": "S", "family_name": "Bastianello", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Advanced magnetic resonance imaging", "neuromyelitis optica", "a multiparametric approach" ], "doi": "10.1177/1352458511431072", "access": "restricted", "takeaways": " Neuroomyelitis optica (NMO) has occult damage in normal-appearing brain tissue, similar to multiple sclerosis (MS) To date, the literature contains no data derived from the combined use of several advanced MRI techniques in the same NMO subjects .", "categories": [] }, { "article_id": 381568, "title": "Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Natalizumab has shown its efficacy in reducing multiple sclerosis (MS) relapses and progression of disability; however, it has been associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML). The differential expression of microRNA (miRNA), the small non-coding RNAs that regulate gene expression, in natalizumab-treated patients has been reported and miRNA have also been described as good candidates for disease biomarkers. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To characterize the effect of natalizumab therapy on the miRNA expression pattern and to search for miRNAs that can predict PML on an individual basis. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> The expression of 754 microRNAs was measured in blood samples from 19 relapsing–remitting MS patients at three time points during natalizumab therapy, using TaqMan OpenArray panels. Two patients included in this study developed PML after more than 2 years of therapy. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We found that the expression level of three miRNAs (let-7c, miR-125a-5p and miR-642) was affected after 6 months of therapy (t6). Furthermore, we observed a differential expression of another three miRNAs (miR-320, miR-320b and miR-629) between the PML and non-PML groups after 12 months of treatment (t12); and a positive correlation was found between therapy time and the expression of miR-320. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458514549402", "published_date": "2014-05-22T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 268817, "given_name": "M", "family_name": "Muñoz-Culla", "ORCID": null, "country": null }, { "author_id": 268818, "given_name": "H", "family_name": "Irizar", "ORCID": null, "country": null }, { "author_id": 268819, "given_name": "T", "family_name": "Castillo-Triviño", "ORCID": null, "country": null }, { "author_id": 268820, "given_name": "M", "family_name": "Sáenz-Cuesta", "ORCID": null, "country": null }, { "author_id": 268821, "given_name": "L", "family_name": "Sepúlveda", "ORCID": null, "country": null }, { "author_id": 268822, "given_name": "I", "family_name": "Lopetegi", "ORCID": null, "country": null }, { "author_id": 268823, "given_name": "A López", "family_name": "de Munain", "ORCID": null, "country": null }, { "author_id": 268824, "given_name": "J", "family_name": "Olascoaga", "ORCID": null, "country": null }, { "author_id": 268825, "given_name": "SE", "family_name": "Baranzini", "ORCID": null, "country": null }, { "author_id": 268826, "given_name": "D", "family_name": "Otaegui", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Blood miRNA expression pattern", "a possible risk marker", "natalizumab-associated progressive multifocal leukoencephalopathy", "multiple sclerosis patients" ], "doi": "10.1177/1352458514534513", "access": "restricted", "takeaways": " Natalizumab has shown its efficacy in reducing MS relapses and progression of disability . However, it has been associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML) The differential expression of microRNAs (miRNAs) in MS patients has been reported and miRNA have also been described as good candidates for disease biomarkers .", "categories": [ { "category_id": 7, "category_description": "", "category_name": "Natalizumab", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ], "article_count": 299 } ] } ] }